Through experiments using TEAD inhibitors (mechanisms of TEAD inhibitors are discussed in section 6), VT101, VT102, and VT103, it has been shown that targeting the Hippo pathway is a potential therapeutic strategy to block cell proliferation in NF2-null primary schwannoma and meningioma cells from human tumors (36). Here, NF2 is linked to schwannoma.